Peptidomic Analysis of Urine from Youths with Early Type 1 Diabetes Reveals Novel Bioactivity of Uromodulin Peptides In Vitro

Abstract

Chronic hyperglycemia is known to disrupt the proteolytic milieu, initiating compensatory and maladaptive pathways in the diabetic kidney. Such changes in intrarenal proteolysis are captured by the urinary peptidome. To elucidate the early kidney response to chronic hyperglycemia, we conducted a peptidomic investigation into urines from otherwise healthy youths with type 1 diabetes and their non-diabetic peers using unbiased and targeted mass spectrometry-based techniques. This cross-sectional study included two separate cohorts for the discovery (n = 30) and internal validation (n = 30) of differential peptide excretion. Peptide bioactivity was predicted using PeptideRanker and subsequently verified in vitro. Proteasix and the Nephroseq database were used to identify putative proteases responsible for peptide generation and examine their expression in diabetic nephropathy. A total of 6550 urinary peptides were identified in the discovery analysis. We further examined the subset of 162 peptides, which were quantified across all thirty samples. Of the 15 differentially excreted peptides (p < 0.05), seven derived from a C-terminal region (589SGSVIDQSRVLNLGPITRK607) of uromodulin, a kidney-specific protein. Increased excretion of five uromodulin peptides was replicated in the validation cohort using parallel reaction monitoring (p < 0.05). One of the validated peptides (SGSVIDQSRVLNLGPI) activated NFκB and AP-1 signaling, stimulated cytokine release, and enhanced neutrophil migration in vitro. In silico analyses highlighted several potential proteases such as hepsin, meprin A, and cathepsin B to be responsible for generating these peptides. In summary, we identified a urinary signature of uromodulin peptides associated with early type 1 diabetes before clinical manifestations of kidney disease and discovered novel bioactivity of uromodulin peptides in vitro. Our present findings lay the groundwork for future studies to validate peptide excretion in larger and broader populations, to investigate the role of bioactive uromodulin peptides in high glucose conditions, and to examine proteases that cleave uromodulin.

The clinical potential of prm-PASEF mass spectrometry

“…Targeted proteomics is gaining more importance as a diagnostic tool as it provides sensitive and accurate quantification of marker panels including native peptides or digested proteins [33]. The performance of the mass spectrometer is independent of biological products like antibodies making the technique independent of antigen interference, production variations, storage problems, and commercial availability.…”

An efficient urine peptidomics workflow identifies chemically defined dietary gluten peptides from patients with celiac disease

“…1 ) is compatible with standard reversed-phase LC-MS/MS instrumentation available in most proteomics laboratories 41 . It is much less time- and labor-intensive than prior approaches, while also allowing the identification of 2-to-10-fold more endogenous human peptides from typical 1-10 mL urine samples 31,32,42,43 . This methodological advance allowed us to undertake a comparative analysis of the wheat-derived urinary peptidomes of patients with CeD and healthy controls.…”

Inhibition of BRD4 Reduces Neutrophil Activation and Adhesion to the Vascular Endothelium Following Ischemia Reperfusion Injury

“…Human primary renal proximal tubular epithelial cells (PTECs) were purchased from Lonza, Basel, Switzerland. The cells were cultured in DMEM/F12 media supplemented with 10% fetal bovine serum, 10 ng/mL epidermal growth factor, 5 μg/mL transferrin, 5 μg/mL insulin, 0.05 μM hydrocortisone, 50 units/mL penicillin, and 50 μg/mL streptomycin and incubated at 37 °C with 5% CO 2 as previously described [ 102 , 104 ]…”